Medically reviewed by Archana Sharma, DO Key Takeaways Leukemia starts in the bone marrow and spreads through the ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Mixed phenotype acute leukemia has qualities of both lymphoid and myeloid leukemias. These mixed qualities make it very difficult to diagnose and treat. The outlook for people with this type of ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...